Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05279092
Other study ID # 2000031881
Secondary ID 000
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 8, 2022
Est. completion date March 2026

Study information

Verified date March 2024
Source Yale University
Contact Jinlei Li, MD PhD
Phone 475-434-4038
Email jinlei.li@yale.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this phase 2 study is to investigate the efficacy of Dexamethasone sodium phosphate (DEX) plus Methylprednisolone acetate (MPA) in combination with plain bupivacaine (B) compared with Liposomal Bupivacaine (LB) in combination with plain bupivacaine on post-surgical pain control among patients undergoing unilateral total knee arthroplasty (TKA) to asses if perineural B-DEX-MPA will result in superior analgesia efficacy as compared to B-LB. This study will also assess if perineural B-DEX-MPA results in improved quality of postoperative recovery as compared to B-LB.


Description:

This phase 2, double blinded and randomized clinical trial will investigate the efficacy of Dexamethasone sodium phosphate (DEX) plus Methylprednisolone acetate (MPA) in combination with plain bupivacaine (B) compared with Liposomal Bupivacaine (LB) in combination with plain bupivacaine on post-surgical pain control among patients undergoing unilateral total knee arthroplasty (TKA). The primary objective of this phase 2 study is to investigate the efficacy of Dexamethasone sodium phosphate (DEX) plus Methylprednisolone acetate (MPA) in combination with plain bupivacaine (B) compared with Liposomal Bupivacaine (LB) in combination with plain bupivacaine on post-surgical pain control among patients undergoing total knee arthroplasty (TKA). The secondary objective of this study is to test the effects of perineural use of B-DEX-MPA vs B-LB on the quality of postoperative recovery as well as surgical outcome and neuropathic pain among patients undergoing unilateral TKA. This study will also assess if perineural B-DEX-MPA results in improved quality of postoperative recovery as compared to B-LB. This will be a single center study at Yale New Haven Hospital (YNHH) performed at two clinical sites: York St. Campus (York Street, New Haven) and St. Raphael Campus (Chapel Street, New Haven). 250 primary, elective and unilateral TKA patients will be enrolled, and equally randomized (1:1 ratio) to receive peripheral nerve blockade with B- LB or B-DEX-MPA.


Recruitment information / eligibility

Status Recruiting
Enrollment 250
Est. completion date March 2026
Est. primary completion date March 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - American Society of Anesthesiologists status I, II and III, elective, primary, unilateral TKA planned for spinal anesthesia with plain 0.5% bupivacaine. Exclusion Criteria: - Refusal of consent - Pregnancy - Conditions making the patient unable to fill out questionnaire online, through email or over the phone including with cognitive dysfunction, psychiatric disorder, or non-English speaking patients, or lack of internet access which would prevent post discharge follow-up electronically - Coagulopathy - Allergy to or for any other reasons cannot use Acetaminophen, Celebrex, local anesthetic bupivacaine, DEX, MPA or LB - Patients on any amounts of opioids within one month of the surgery date, any substance abuse such as regular marijuana user (more frequent than once per month) - Insulin dependent or uncontrolled diabetes defined as, day of surgery finger stick glucose >200mg/dl, or HbA1C > 8.0% - Peripheral Nerve Block site or systemic infection - Immune compromise (e.g., HIV, chronic glucocorticoid use) - Severe pre-existing neuropathy - TKA for indications other than osteoarthritis such as post-traumatic injury or rheumatoid arthritis, history of surgery in the ipsilateral knee joint, revision TKA or bilateral TKA - Severe hepatic or renal dysfunction (GFR <50 ml/min) - Actual body weight <60 kg - Patients with active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and non-specific ulcerative colitis

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bupivacaine-Liposomal Bupivacaine
Adductor canal block comprised of 20 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 30 ml; 10 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 20 ml will be administered through an iPACK block
Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate
Adductor canal block comprised of 30 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml); 20 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml) will be administered through an iPACK block.

Locations

Country Name City State
United States Yale New Haven Hospital Saint Raphael Campus New Haven Connecticut
United States Yale New Haven Hospital York Street Campus New Haven Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Yale University Department of Anesthesiology Faculty Development Fund

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Postoperative Knee Pain Score Average postoperative knee pain scores for the first two postoperative days using Visual analogue scale (VAS) pain score. Score range from 0 (no pain) to 10 (worst pain possible). Day 1 and Day 2
Primary Postoperative opioid consumption In-hospital postoperative opioid consumption in oral milligram morphine equivalent (OME) will be monitored up to 48-hour between anesthesia end time and discharge time From anesthesia end time to discharge time, up to 48 hours
Secondary Average Postoperative Knee Pain Score Average postoperative knee pain scores for postoperative day 7 using Visual analogue scale (VAS) pain score. Score range from 0 (no pain) to 10 (worst pain possible). Day 7
Secondary Worst and best pain score Worst and best postoperative knee pain scores for days 1, 2 and 7 using Visual analogue scale (VAS) pain score. Score range from 0 (no pain) to 10 (worst pain possible). Day 1, Day 2 and Day 7
Secondary Change in functional pain using Brief Pain Inventory (BPI) Compare functional pain using the BPI at baseline, 6 weeks and 3 months. The BPI scale defines pain as follows: Score: 1 - 4 = Mild Pain, Score: 5 - 6 = Moderate Pain, Score: 7 - 10 = Severe Pain. baseline, 6 weeks and 3 months
Secondary Change in neuropathic pain using PainDetect Compare neuropathic pain at baseline, 6 weeks and 3 months using PainDetect: a nine-item questionnaire that consists of seven sensory symptom items for pain that are graded from 0= never to 5= strongly, one temporal item on pain-course pattern graded -1 to +1, and one spatial item on pain radiation graded 0 for no radiation or +2 for radiating pain. baseline, 6 weeks and 3 months
Secondary Persistent opioid use using Yale Postoperative Recovery Scale Persistent opioid use will be compared using the Yale Postoperative Recovery Scale on postoperative day 7, 6 weeks and 3 months. It is comprised of 3 free-text questions: Is patient still taking opioid medications, Yes or No; The number of pills left in pill box;and Has the patient needed a prescription refill, Yes or No. Day 7, 6 weeks and 3 months
Secondary Persistent opioid use using NarX Persistent opioid use will be compared using the NarX score at 6 weeks and 3 months, scores range from 000-999; higher scores indicate more opioid usage 6 weeks and 3 months
Secondary Change in Quality of Recovery 40 questionnaire 40 questions assessing quality of recovery graded on a five-point Likert scale, total score range from 40 (extremely poor recovery) to 200 (excellent recovery) Day 1, 2 and 7
Secondary Prosthetic joint range of motion Compare prosthetic joint range of motion using the patient's electronic medical record as reported by the physical therapist at baseline, day 0, day 1, and day 2 baseline, day 0, day 1 and day 2
Secondary Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Global-10 The PROMIS Global-10 is a 10-item patient-reported questionnaire that measures changes in general health in which the response options are presented as 5-point scale, 5 (without any difficulty) to 1 (Unable to do). Higher scores indicate a healthier patient. 6 weeks and 3 months
Secondary Change in knee functional status using Knee injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS JR) Compare knee functional status using KOOS JR at 6 weeks and 3 months after surgery, Scores range from 0 to 100 with a score of 0 indicating total knee disability and 100 indicating perfect knee health. 6 weeks and 3 months
Secondary Length of stay The patient's post surgical length of stay in the hospital will be compared between treatment groups. from the start of the surgery to discharge from hospital, up to 48 hours
Secondary Change in glucose Compare the change in postoperative serum glucose from baseline only for participants that have an overnight hospital stay baseline, day 0, day 1 and day 2
Secondary Change in white blood cell count (WBC) Compare the change in postoperative WBC from baseline only for participants that have an overnight hospital stay baseline, day 0, day 1 and day 2
Secondary Absolute value of Interleukin 1 beta (IL-1b) Absolute value IL-1b at postoperative day 1 only for participants that have an overnight hospital stay day 1
See also
  Status Clinical Trial Phase
Terminated NCT04040985 - Legion Primary Safety and Efficacy N/A
Completed NCT03286543 - Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System N/A
Not yet recruiting NCT04594447 - Physica System KR vs Physica System CR (K-20) N/A
Completed NCT02413996 - Effects of Virtual Reality Rehabilitation in Patients With Total Knee Arthroplasty N/A
Completed NCT01500252 - Patellar Resurfacing Versus Patellar Retention in Total Knee Arthroplasty - A Randomized Clinical Trial Phase 4
Completed NCT04081493 - The Efficacy of Low-load Blood Flow Restricted Resistance Before TKR N/A
Active, not recruiting NCT03339557 - Comparison of Three Knee Replacements N/A
Enrolling by invitation NCT04513145 - Adductor Canal Block Phase 2/Phase 3
Completed NCT06045078 - Aromatherapy in Total Knee Replacement N/A
Completed NCT02468934 - Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty (TKA) Using the SPRINT System N/A
Completed NCT02914210 - Virtual vs. Traditional Physical Therapy Following Total Knee Replacement N/A
Withdrawn NCT01523418 - Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement) N/A
Completed NCT00795223 - Comparative Pain Control Between 0.2 or 0.3 Spinal Morphine and 0.25 or 0.5 % Bupivacaine for FNB After TKA Phase 4
Completed NCT01307202 - Morphine Consumption in Joint Replacement Patients, With or Without Gabapentin Treatment N/A
Completed NCT01515449 - Predictors of Poor Outcomes in 1038 Sigma Knees N/A
Completed NCT01522781 - 10 Year Outcome of Total Knee Replacement (TKR) Using Sigma Prosthesis N/A
Completed NCT04166539 - Neurotoxicity and Cardiotoxicity in Total Joint Arthroplasty
Completed NCT03454256 - Virtual Reality Rehabilitation in Patients With Total Knee Replacement N/A
Enrolling by invitation NCT06118073 - Effect of Mindfulness on Pain After Total Knee Arthroplasty N/A
Completed NCT05597046 - Qualitative Interviews With Healthcare Professionals